A self-balancing exoskeleton that enables users to move in multiple directions hands-free has been cleared by the U.S. Food and Drug Administration (FDA) for stroke rehabilitation.
Since 2020, French developers Wandercraft have deployed 22 copies of their posture training “Atalante” exoskeleton in clinical settings. With FDA backing, they hope to deliver the first “Atalante” exoskeletons to the United States during the first quarter of 2023.
According to the Centers for Disease Control and Prevention (CDC), every year, more than 795,000 people in the U.S. suffer from a stroke, a leading cause of serious long-term disability.
✨ Wandercraft has developed Atalante. An exoskeleton that is helping wheelchair users walk again in clinical centers, especially for re-education purposes.— Elmo Motion Control (@ElmoLtd) October 4, 2022
🚀 Powered by Elmo Twitter servo drive modules.
Watch the full story here:https://t.co/uvoVAl6CDA@ExoWandercraft pic.twitter.com/klmH5rHAec
Fastened to his shoulders, chest, waist, knees, and feet, the exoskeleton allowed Oscar - who has a genetic neurological condition where his nerves do not send enough signals needed to his legs - to walk across the room and turn around.
Wandercraft chairman Nicolas Simon and CEO Matthieu Masselin tell us how they want their exoskeletons to one day be as common as wheelchairs pic.twitter.com/YWfnviUM0f— Reuters (@Reuters) November 8, 2022